All entries for: Dermatology

May 8, 2026

Novartis

Layoffs

Basel, Baselstadt

10,000+ employees

Novartis plans to close a production facility in Wehr, Germany, by the end of 2028, a move that’s expected to eliminate 220 jobs, the Swiss pharma announced May 5.

The site, which makes solid oral dosage forms such as tablets and capsules for mostly established Novartis products, is no longer competitive, the company noted in its announcement. Novartis said it remains committed to Germany as a business location.

The pharma is investing 35 million euros (about $41 million) into a new production facility for radioligand therapies in Halle, Germany. The site will produce personalized cancer therapies for patients in Germany and should be operational in 2027, according to the announcement.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple, Oncology

Drug Type: Biologic, Small Molecule

Source

May 7, 2026

Corvus Pharmaceuticals, Inc.

Neutral Outlook

Burlingame, CA

51-200 employees

While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.

Disease Area: Dermatology, Hematology, Immune Diseases, Oncology

Drug Type: Biologic, Small Molecule

Source

April 30, 2026

Celularity Inc

Neutral Outlook

Florham Park, NJ

51-200 employees

The effect of IRA on our business and the healthcare industry in general is not yet known.

Disease Area: Dermatology

Drug Type: Biologic

Source

April 28, 2026

Novartis

Layoffs

Basel, Baselstadt

10,000+ employees

For the second month in a row, Novartis is chipping away at its East Hanover, New Jersey, workforce. The Swiss pharma is laying off 60 employees in the city effective July 24 to Nov. 20, according to a Worker Adjustment and Retraining Notification Act (WARN) notice. Novartis is also letting go of 114 people in East Hanover from June 26 to Nov. 27, according to a March WARN alert.

Novartis also trimmed its workforce in 2025, putting 1,069 employees—including 485 in East Hanover—on the chopping block over a multiyear period. The largest round of layoffs involved 550 employees in Switzerland who will be out of work by the end of 2027.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple, Oncology

Drug Type: Biologic, Small Molecule

Source

March 31, 2026

Palvella Therapeutics, Inc.

Neutral Outlook

Wayne, PA

1-50 employees

Several healthcare reform proposals culminated in the enactment of the Inflation Reduction Act of 2022 (“IRA”) for example, contains substantial drug pricing and other reforms to Medicare’s coverage of pharmaceuticals. Among other things, the IRA eliminated, beginning in 2025, the coverage gap under Medicare Part D by significantly lowering the enrollee maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program (replacing the former Coverage Gap Discount Program), 10% of Part D enrollees’ prescription costs for brand drugs below the out-of-pocket limit, and 20% once the out-of-pocket limit has been reached.

Disease Area: Dermatology, Rare Diseases

Drug Type: Small Molecule

Source

March 31, 2026

Connect Biopharma Holding Ltd

Neutral Outlook

San Diego, CA

51-200 employees

For that and other reasons, it is currently unclear how the IRA will be effectuated.

Disease Area: Dermatology, Immune Diseases

Drug Type: Biologic, Small Molecule

Source

March 30, 2026

Veradermmics, Inc

Neutral Outlook

New Haven, CT

1-50 employees

For example, the Inflation Reduction Act of 2022, or the IRA, which is having a significant and ongoing impact on the pharmaceutical industry, includes a number of changes intended to address rising prescription drug prices in Medicare Parts B and D, such as caps on Medicare Part D out-of-pocket costs and a drug price negotiation program for certain high-spend Medicare Part B and D drugs.

Disease Area: Dermatology

Drug Type: Small Molecule

Source

March 26, 2026

Journey Medical Corp

Neutral Outlook

Scottsdale, AZ

51-200 employees

The Inflation Reduction Act of 2022 (the “IRA”) contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services (“HHS”) that would require manufacturers to charge a negotiated “maximum fair price” for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs.

Disease Area: Dermatology

Drug Type: Small Molecule

Source

March 26, 2026

Quoin Pharmaceuticals, Ltd.

Neutral Outlook

Ashburn, VA

1-50 employees

The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. These provisions have been and may continue to be subject to legal challenges. It is unclear what policies will be advanced with respect to IRA implementation and other drug pricing proposals.

Disease Area: Dermatology, Rare Diseases

Drug Type: Biologic, Small Molecule

Source

March 23, 2026

Avalo Therapeutics

Neutral Outlook

Wayne, PA

1-50 employees

The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA’s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.

Disease Area: Chronic Disease, Dermatology, Immune Diseases

Drug Type: Biologic, Small Molecule

Source